Washington, D.C. – The Natural Products Association today, in a Request for Information (RFI) response, submitted its proposal to regulate cannabidiol (CBD) to the United States House and Senate. The House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ) along with Senate Health, Education, Labor, and Pensions Committee Chair Bernie Sanders (I-VT) and Ranking Member Bill Cassidy, M.D. (R-LA), requested the information from a range of subject matter experts and stakeholders intimately involved with the Food and Drug Administration (FDA).
NPA’s response can be viewed here.
“For more than five years, Americans have been asking the FDA to make a safety determination for CBD. In that time, NPA has worked with Congress and the states to establish appropriate measures and even petitioned the FDA to exercise enforcement discretion in a specific and selective manner consistent with the premarket safety review of a new dietary ingredient notification,” said Daniel Fabricant, Ph.D., president and CEO of the NPA.
“Instead of using existing regulatory authority, FDA has resisted fulfilling their mandate for years and now chasing the fantasy of a ‘center’ for hemp and cannabis products that would mimic the Center for Tobacco Products. Through DSHEA, Congress has provided the FDA with broad authority to review safety data for new dietary ingredients like CBD to enter commerce. Our proposal demonstrates that putting a clock on FDA to use existing authority is the most efficient and straightforward pathway for public health and to stabilize a robust marketplace for dietary supplements and foods containing CBD.”
